mAbs targeted against CCL2 and CSF-1R to reduce TAM recruitment and/or survival have been investigated in phase I clinical trials involving ovarian cancer patients (Figure 3) (NCT02526017) [64]. This evidence concerns the gene CSF1R and ovarian carcinoma.